Canopus BioPharma Inc. is determined to ensure that, as a company, they are at the forefront of discoveries, developments and commercial breakthroughs within the pharmaceutical industry.
Canopus BioPharma comprises a unique and dynamic team focused on commercialising its three leading pharmaceutical products for the treatment of Hepatitis C, Mucositis and Influenza. Canopus BioPharma has an impressive pipeline of technologies forming a strong foundation for the future.
